These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15540903)

  • 1. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.
    Ogura M; Morishima Y; Kobayashi Y; Uike N; Sugai S; Chou T; Kasai M; Miura I; Murayama T; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Tobinai K;
    Int J Hematol; 2004 Oct; 80(3):267-77. PubMed ID: 15540903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
    Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
    Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma.
    Saven A; Emanuele S; Kosty M; Koziol J; Ellison D; Piro L
    Blood; 1995 Sep; 86(5):1710-6. PubMed ID: 7655003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma.
    Tulpule A; Schiller G; Harvey-Buchanan LA; Lee M; Espina BM; Khan AU; Boswell W; Nathwani B; Levine AM
    Cancer; 1998 Dec; 83(11):2370-6. PubMed ID: 9840537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab.
    Tobinai K; Watanabe T; Tanimoto K; Maruyama D; Nakata M; Itoh K; Morishima Y; Ogura M; Usui N; Kasai M; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y
    Cancer Sci; 2009 Jul; 100(7):1344-50. PubMed ID: 19432900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
    Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
    J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.
    Tobinai K; Uike N; Saburi Y; Chou T; Etoh T; Masuda M; Kawano F; Matsuoka M; Taguchi H; Makino T; Asano Y; Tamura K; Ohashi Y;
    Int J Hematol; 2003 Jun; 77(5):512-7. PubMed ID: 12841391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
    Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS
    Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
    Kong LR; Huang CF; Hakimian D; Variakojis D; Klein L; Kuzel TM; Gordon LI; Zanzig C; Wollins E; Tallman MS
    Cancer; 1998 Mar; 82(5):957-64. PubMed ID: 9486587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.
    Robak T; Smolewski P; Urbanska-Rys H; Gora-Tybor J; Blonski JZ; Kasznicki M
    Leuk Lymphoma; 2004 May; 45(5):937-44. PubMed ID: 15291352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse.
    Rummel MJ; Chow KU; Jäger E; Hossfeld DK; Bergmann L; Peters HD; Hansmann ML; Meyer A; Hoelzer D; Mitrou PS
    Ann Oncol; 1999 Jan; 10(1):115-7. PubMed ID: 10076731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma.
    Liliemark J; Porwit A; Juliusson G
    Leuk Lymphoma; 1997 Apr; 25(3-4):313-8. PubMed ID: 9168441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.
    Hoffman M; Tallman MS; Hakimian D; Janson D; Hogan D; Variakogis D; Kuzel T; Gordon LI; Rai K
    J Clin Oncol; 1994 Apr; 12(4):788-92. PubMed ID: 7908690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
    Robak T; Lech-Maranda E; Janus A; Blonski J; Wierzbowska A; Gora-Tybor J
    Leuk Lymphoma; 2007 Jun; 48(6):1092-101. PubMed ID: 17577772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas.
    Rummel MJ; Chow KU; Jäger E; Leimer L; Hossfeld DK; Bergmann L; Peters HD; Hansmann ML; Meyer A; Hoelzer D; Mitrou PS
    Leuk Lymphoma; 1999 Sep; 35(1-2):129-38. PubMed ID: 10512170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma.
    Saven A; Lee T; Kosty M; Piro L
    J Clin Oncol; 1996 Jul; 14(7):2139-44. PubMed ID: 8683247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
    Robak T; Góra-Tybor J; Lech-Marańda E; Błoński JZ; Kasznicki M
    Eur J Haematol; 2001 Mar; 66(3):188-94. PubMed ID: 11350487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.
    Bennani NN; LaPlant BR; Ansell SM; Habermann TM; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Colgan JP; Markovic SN; Nowakowski GS; Macon WR; Reeder CB; Mikhael JR; Northfelt DW; Ghobrial IM; Witzig TE
    Am J Hematol; 2017 May; 92(5):448-453. PubMed ID: 28211162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study.
    Takamatsu Y; Suzumiya J; Ogata K; Katayose K; Sasaki H; Ishitsuka K; Kimura N; Tamura K
    J Clin Exp Hematop; 2009 Nov; 49(2):69-75. PubMed ID: 19907111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Haq R; Sawka CA; Franssen E; Berinstein NL
    Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.